Valneva SE (INRLF)
OTCMKTS
· Delayed Price · Currency is USD
3.100
0.00 (0.00%)
Jul 2, 2025, 4:00 PM EDT
Valneva SE Revenue
Valneva SE had revenue of 49.23M EUR in the quarter ending March 31, 2025, with 50.31% growth. This brings the company's revenue in the last twelve months to 186.06M, up 21.64% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
186.06M EUR
Revenue Growth
+21.64%
P/S Ratio
2.47
Revenue / Employee
260.95K EUR
Employees
713
Market Cap
496.89M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 84.04M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Valneva SE News
- 26 days ago - UK's MHRA suspends Valneva's chikungunya vaccine for elderly - Reuters
- 4 weeks ago - Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 - Benzinga
- 4 weeks ago - Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 4 weeks ago - Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Valneva to Participate at U.S. and European Investor Conferences in June - GlobeNewsWire
- 7 weeks ago - Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States - GlobeNewsWire
- 2 months ago - Valneva SE (VALN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Valneva SE 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha